Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Pharmacokinetic Study of JTS-661 (serlopitant) in Hemodialysis Patients
jRCT2080223686Phase 1
- Sponsor
- Japan Tobacco
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of serlopitant in chronic kidney disease-associated pruritus (CKD-aP), sponsored by Japan Tobacco. Primary endpoint: Primary pharmacokinetic parameters of serlopitant in hemodialysis patients.
02
Drugs
serlopitant
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on jRCT2080223686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223686.